Background The recommended doses for direct oral anticoagulants (DOACs) to prevent
stroke and systemic embolism (SE) in patients with atrial fibrillation (AF) are described in …

Background COVID-19 is associated with inflammation and an increased risk of
thromboembolic complications. Prophylactic doses of low-molecular-weight heparin have …

Background: Atrial fibrillation is associated with increased risks of death, stroke/systemic
embolism, and bleeding (incurred by antithrombotic therapy), which may occur early after …

Background Asymptomatic atrial fibrillation is often detected incidentally. Prognosis and
optimal therapy for asymptomatic compared with symptomatic atrial fibrillation is uncertain …

Introduction A principal aim of the Global Anticoagulant Registry in the FIELD-Atrial
Fibrillation (GARFIELD-AF) was to document changes in treatment practice for patients with …

In atrial fibrillation (AF), lower risks of death and bleeding with non-vitamin-K oral
anticoagulants (NOACs) were reported in meta-analyses of controlled trials, but whether …

Background Incidence rates of various cancers are increasing in Arab countries and are
expected to reach those of industrialized ones in few decades. This paper aimed to describe …

Background Estimates of cancer prevalence are widely based on limited duration, often
including patients living after a cancer diagnosis made in the previous 5 years and less …

A higher frequency of early onset female breast cancers (BC) has been observed in
low/middle income countries than in high income countries. We quantified the role of …

Aims To determine whether the Global Anticoagulant Registry in the FIELD–Atrial Fibrillation
(GARFIELD-AF) integrated risk tool predicts mortality, non-haemorrhagic stroke/systemic …